Loading…

Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis

Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detecti...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical and experimental medicine 2015-01, Vol.8 (7), p.11683-11691
Main Authors: Zhang, Yimin, Yang, Jun, Li, Hongjuan, Wu, Yihua, Zhang, Honghe, Chen, Wenhu
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 11691
container_issue 7
container_start_page 11683
container_title International journal of clinical and experimental medicine
container_volume 8
creator Zhang, Yimin
Yang, Jun
Li, Hongjuan
Wu, Yihua
Zhang, Honghe
Chen, Wenhu
description Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detection. We searched PubMed, Embase, Medline, and Wanfang databases for studies that evaluated the diagnostic validity of CA19-9, CA242, and CEA between January 1990 and September 2014. Data were analyzed by Meta-Disc and STATA software. A total of 21 studies including 3497 participants, which fulfilled the inclusion criteria were considered for analysis. The pooled sensitivities for CA19-9, CA242, and CEA were 75.4 (95% CI: 73.4-77.4), 67.8 (95% CI: 65.5-70), and 39.5 (95% CI: 37.3-41.7), respectively. The pooled specificities of CA19-9, CA242, and CEA were 77.6 (95% CI: 75.4-79.7), 83 (95% CI: 81-85), and 81.3 (95% CI: 79.3-83.2), respectively. Parallel combination of CA19-9+CA242 has a higher sensitivity (89, 95% CI: 80-95) without impairing the specificity (75, 95% CI: 67-82). Our meta-analysis showed that CA242 and CA19-9 have better performance in the diagnosis of pancreatic cancer than CEA. Furthermore, parallel combination test of CA19-9+CA242 could be of better diagnostic value than individual CA242 or CA19-9 test.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4565388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1713944971</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-e0f4e14ef00378d02c708bd262170b08c6e51249ce06ca6b429e149788453f5a3</originalsourceid><addsrcrecordid>eNpVkEtLxDAUhYsozjj6FyRLFxbyapq4EIYyPmDAzbhxU9L0dibapjVphfn3BhxlXJ0D93A-7jlJ5kRxnGYKk9MjP0suQnjHWBDK1Hkyo4JJjHE2T942U9d71Gn_AT6gYklUqm6jUk6RdjUqVktkHRp3gGqrt64PNqC-QYN2xoMerUEmWvB3SKMORp1qp9t9TF0mZ41uA1wddJG8Pqw2xVO6fnl8LpbrdKBCjCnghgPh0GDMclljanIsq5oKSnJcYWkEZIRyZQALo0XFqYpxlUvJM9Zkmi2S-5_eYao6qA240eu2HLyNX-3LXtvy_8XZXbntv0qeiYxJGQtuDgW-_5wgjGVng4G21Q76KZQkJ0zxiCQxen3M-oP8Dsq-Af7mcKM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1713944971</pqid></control><display><type>article</type><title>Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis</title><source>PubMed Central</source><creator>Zhang, Yimin ; Yang, Jun ; Li, Hongjuan ; Wu, Yihua ; Zhang, Honghe ; Chen, Wenhu</creator><creatorcontrib>Zhang, Yimin ; Yang, Jun ; Li, Hongjuan ; Wu, Yihua ; Zhang, Honghe ; Chen, Wenhu</creatorcontrib><description>Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detection. We searched PubMed, Embase, Medline, and Wanfang databases for studies that evaluated the diagnostic validity of CA19-9, CA242, and CEA between January 1990 and September 2014. Data were analyzed by Meta-Disc and STATA software. A total of 21 studies including 3497 participants, which fulfilled the inclusion criteria were considered for analysis. The pooled sensitivities for CA19-9, CA242, and CEA were 75.4 (95% CI: 73.4-77.4), 67.8 (95% CI: 65.5-70), and 39.5 (95% CI: 37.3-41.7), respectively. The pooled specificities of CA19-9, CA242, and CEA were 77.6 (95% CI: 75.4-79.7), 83 (95% CI: 81-85), and 81.3 (95% CI: 79.3-83.2), respectively. Parallel combination of CA19-9+CA242 has a higher sensitivity (89, 95% CI: 80-95) without impairing the specificity (75, 95% CI: 67-82). Our meta-analysis showed that CA242 and CA19-9 have better performance in the diagnosis of pancreatic cancer than CEA. Furthermore, parallel combination test of CA19-9+CA242 could be of better diagnostic value than individual CA242 or CA19-9 test.</description><identifier>ISSN: 1940-5901</identifier><identifier>EISSN: 1940-5901</identifier><identifier>PMID: 26380005</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Review</subject><ispartof>International journal of clinical and experimental medicine, 2015-01, Vol.8 (7), p.11683-11691</ispartof><rights>IJCEM Copyright © 2015 2015</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565388/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565388/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26380005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yimin</creatorcontrib><creatorcontrib>Yang, Jun</creatorcontrib><creatorcontrib>Li, Hongjuan</creatorcontrib><creatorcontrib>Wu, Yihua</creatorcontrib><creatorcontrib>Zhang, Honghe</creatorcontrib><creatorcontrib>Chen, Wenhu</creatorcontrib><title>Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis</title><title>International journal of clinical and experimental medicine</title><addtitle>Int J Clin Exp Med</addtitle><description>Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detection. We searched PubMed, Embase, Medline, and Wanfang databases for studies that evaluated the diagnostic validity of CA19-9, CA242, and CEA between January 1990 and September 2014. Data were analyzed by Meta-Disc and STATA software. A total of 21 studies including 3497 participants, which fulfilled the inclusion criteria were considered for analysis. The pooled sensitivities for CA19-9, CA242, and CEA were 75.4 (95% CI: 73.4-77.4), 67.8 (95% CI: 65.5-70), and 39.5 (95% CI: 37.3-41.7), respectively. The pooled specificities of CA19-9, CA242, and CEA were 77.6 (95% CI: 75.4-79.7), 83 (95% CI: 81-85), and 81.3 (95% CI: 79.3-83.2), respectively. Parallel combination of CA19-9+CA242 has a higher sensitivity (89, 95% CI: 80-95) without impairing the specificity (75, 95% CI: 67-82). Our meta-analysis showed that CA242 and CA19-9 have better performance in the diagnosis of pancreatic cancer than CEA. Furthermore, parallel combination test of CA19-9+CA242 could be of better diagnostic value than individual CA242 or CA19-9 test.</description><subject>Review</subject><issn>1940-5901</issn><issn>1940-5901</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkEtLxDAUhYsozjj6FyRLFxbyapq4EIYyPmDAzbhxU9L0dibapjVphfn3BhxlXJ0D93A-7jlJ5kRxnGYKk9MjP0suQnjHWBDK1Hkyo4JJjHE2T942U9d71Gn_AT6gYklUqm6jUk6RdjUqVktkHRp3gGqrt64PNqC-QYN2xoMerUEmWvB3SKMORp1qp9t9TF0mZ41uA1wddJG8Pqw2xVO6fnl8LpbrdKBCjCnghgPh0GDMclljanIsq5oKSnJcYWkEZIRyZQALo0XFqYpxlUvJM9Zkmi2S-5_eYao6qA240eu2HLyNX-3LXtvy_8XZXbntv0qeiYxJGQtuDgW-_5wgjGVng4G21Q76KZQkJ0zxiCQxen3M-oP8Dsq-Af7mcKM</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Zhang, Yimin</creator><creator>Yang, Jun</creator><creator>Li, Hongjuan</creator><creator>Wu, Yihua</creator><creator>Zhang, Honghe</creator><creator>Chen, Wenhu</creator><general>e-Century Publishing Corporation</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis</title><author>Zhang, Yimin ; Yang, Jun ; Li, Hongjuan ; Wu, Yihua ; Zhang, Honghe ; Chen, Wenhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-e0f4e14ef00378d02c708bd262170b08c6e51249ce06ca6b429e149788453f5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yimin</creatorcontrib><creatorcontrib>Yang, Jun</creatorcontrib><creatorcontrib>Li, Hongjuan</creatorcontrib><creatorcontrib>Wu, Yihua</creatorcontrib><creatorcontrib>Zhang, Honghe</creatorcontrib><creatorcontrib>Chen, Wenhu</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yimin</au><au>Yang, Jun</au><au>Li, Hongjuan</au><au>Wu, Yihua</au><au>Zhang, Honghe</au><au>Chen, Wenhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis</atitle><jtitle>International journal of clinical and experimental medicine</jtitle><addtitle>Int J Clin Exp Med</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>8</volume><issue>7</issue><spage>11683</spage><epage>11691</epage><pages>11683-11691</pages><issn>1940-5901</issn><eissn>1940-5901</eissn><abstract>Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detection. We searched PubMed, Embase, Medline, and Wanfang databases for studies that evaluated the diagnostic validity of CA19-9, CA242, and CEA between January 1990 and September 2014. Data were analyzed by Meta-Disc and STATA software. A total of 21 studies including 3497 participants, which fulfilled the inclusion criteria were considered for analysis. The pooled sensitivities for CA19-9, CA242, and CEA were 75.4 (95% CI: 73.4-77.4), 67.8 (95% CI: 65.5-70), and 39.5 (95% CI: 37.3-41.7), respectively. The pooled specificities of CA19-9, CA242, and CEA were 77.6 (95% CI: 75.4-79.7), 83 (95% CI: 81-85), and 81.3 (95% CI: 79.3-83.2), respectively. Parallel combination of CA19-9+CA242 has a higher sensitivity (89, 95% CI: 80-95) without impairing the specificity (75, 95% CI: 67-82). Our meta-analysis showed that CA242 and CA19-9 have better performance in the diagnosis of pancreatic cancer than CEA. Furthermore, parallel combination test of CA19-9+CA242 could be of better diagnostic value than individual CA242 or CA19-9 test.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>26380005</pmid><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1940-5901
ispartof International journal of clinical and experimental medicine, 2015-01, Vol.8 (7), p.11683-11691
issn 1940-5901
1940-5901
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4565388
source PubMed Central
subjects Review
title Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A20%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20markers%20CA19-9,%20CA242%20and%20CEA%20in%20the%20diagnosis%20of%20pancreatic%20cancer:%20a%20meta-analysis&rft.jtitle=International%20journal%20of%20clinical%20and%20experimental%20medicine&rft.au=Zhang,%20Yimin&rft.date=2015-01-01&rft.volume=8&rft.issue=7&rft.spage=11683&rft.epage=11691&rft.pages=11683-11691&rft.issn=1940-5901&rft.eissn=1940-5901&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1713944971%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p266t-e0f4e14ef00378d02c708bd262170b08c6e51249ce06ca6b429e149788453f5a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1713944971&rft_id=info:pmid/26380005&rfr_iscdi=true